R2与R-miniCHOP方案治疗老年B细胞非霍奇金淋巴瘤患者的近期疗效比较  

Comparison of the short-term efficacy of R2 and R-miniCHOP regimens in the treatment of elderly patients with B-cell non-Hodgkin's lymphoma

作　　者：刘萍 卢英豪 郑琳 王建宇 陈莹 王季石 LIU Ping;LU Yinghao;ZHENG Lin;WANG Jianyu;CHEN Ying;WANG Jishi(The Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550004,China)

机构地区：[1]贵州医科大学附属医院,贵州贵阳550004

出　　处：《现代肿瘤医学》2025年第6期932-937,共6页Journal of Modern Oncology

基　　金：国家自然科学基金地区基金(编号:82160704);贵州省卫生健康委科学技术基金项目(编号:gzwkj2021-158);贵州医科大学附属医院国家自然科学基金培育计划项目资助(编号:gyfynsfc-2021-43);贵州医科大学附属医院博士科研启动基金项目(编号:gyfybsky-2021-51)。

摘　　要：目的:比较观察R2(来那度胺+利妥昔单抗)与R-miniCHOP方案在老年B细胞非霍奇金淋巴瘤患者中的近期疗效及不良反应。方法:回顾性分析我院自2022年01月至2023年09月间接受R2(来那度胺+利妥昔单抗)方案(10例)或R-miniCHOP方案(12例)治疗且资料完整的老年(≥65岁)患者的临床资料,观察比较两组患者的疗效、不良反应发生情况及疾病转归。结果:R2组总反应率(ORR)为60%,R-miniCHOP组为50%,无统计学差异。两组中位随访时间分别为14和16.5个月,1年OS率(80%vs 83.3%,P>0.05)、1年PFS率(70%vs 66.7%,P>0.05)均无统计学差异。两组的不良反应主要是血液学不良反应,其发生率比较有统计学意义(P<0.05)。结论:R2与R-miniCHOP方案治疗老年B细胞非霍奇金淋巴瘤患者近期疗效相近,但R2组不良反应发生率低,安全可耐受。Objective:To compare the recent efficacy and adverse effects of the R2(lenalidomide+rituximab)and R-miniCHOP regimens in elderly patients with B-cell non-Hodgkin's lymphoma under preliminary observation.Methods:We retrospectively analyzed the clinical data of elderly(≥65 years old)patients treated with R2(lenalidomide+rituximab)regimen(10 patients)or R-mini CHOP regimen(12 patients)with complete data from January 2022 to September 2023 in our hospital,and compared the therapeutic efficacy,the occurrence of adverse reactions,and the regression of disease between the two groups.Results:The overall response rate(ORR)was 60%in the R2 group and 50%in the R-mini CHOP group,with no statistical difference.The median follow-up time was 14 and 16.5 months,and there was no statistically significant difference in the 1-year OS rate(80%vs 83.3%,P>0.05)and 1-year PFS rate(70%vs 66.7%,P>0.05).The adverse reactions of the two groups were mainly hematological adverse reactions,and the incidence was statistically significant(P<0.05).Conclusion:The recent efficacy of R2 and R-miniCHOP regimens in the treatment of elderly patients with B-cell non-Hodgkin's lymphoma is similar,but the incidence of adverse reactions in the R2 group is low,safe and tolerable.

关 键 词：B细胞非霍奇金淋巴瘤 来那度胺 利妥昔单抗 疗效 

分 类 号：R733.4[医药卫生—肿瘤]